Watch CRBP. Know when insiders buy.
One email the day a filing lands. Free.
CRBP
Corbus Pharmaceuticals Holdings, Inc.
8.24
−0.62 −7.00%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
68
PASS · shorts 68
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $159.4MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$101.9MNET CASH $5.5M52W 7.38 – 19.36SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$36.2M | −$35M | — | -1.81 | −$29.6M | $6K | −$29.6M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$24.3M | −$23M | — | -1.23 | −$25.6M | $6K | −$25.6M | May 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$22M | −$20.6M | — | -1.17 | −$15.9M | — | — | Mar 9 |
| Q3 2025 · Sep 30 | — | — | — | −$24.4M | −$23.3M | — | -1.90 | −$15.6M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$19.2M | −$17.7M | — | -1.44 | −$16.6M | $0 | −$16.6M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$19.8M | −$17M | — | -1.39 | −$16.4M | $0 | −$16.4M | May 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$12.6M | −$9.5M | — | -0.76 | −$10.9M | — | — | Mar 9 |
| Q3 2024 · Sep 30 | — | — | — | −$15.5M | −$13.8M | — | -1.15 | −$13.9M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$11M | −$10M | — | -0.90 | −$8.9M | — | — | Aug 5 |
| Q1 2024 · Mar 31 | — | — | — | −$9.6M | −$6.9M | — | -0.83 | −$8M | — | — | May 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$10.1M | −$8M | — | -1.79 | −$6M | $0 | −$6M | Mar 11 |
| Q3 2023 · Sep 30 | — | — | — | −$9.5M | −$10.1M | — | -2.27 | −$7.2M | $0 | −$7.2M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$85.3M | −$78.5M | — | -5.90 | −$64.5M | $7K | −$64.5M | — | — |
| FY2024 · to Dec 31 | — | — | −$48.7M | −$40.2M | — | -3.68 | −$41.8M | $0 | −$41.8M | — | — |
| FY2023 · to Dec 31 | — | — | −$45.1M | −$44.6M | — | -10.31 | −$36.1M | $0 | −$36.1M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$39.8M | −$42.3M | — | -10.15 | −$37.5M | $13K | −$37.6M | — | — |
| FY2021 · to Dec 31 | $882K | — | −$56M | −$45.6M | -5176.4% | -11.15 | −$48.2M | $54K | −$48.2M | — | — |
| FY2020 · to Dec 31 | $3.9M | — | −$122.8M | −$111.3M | -2826.1% | -1.42 | −$99.7M | $484K | −$100.2M | — | — |
Every number comes from Corbus Pharmaceuticals Holdings, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.